TY - JOUR AU - Postmus, P. AU - Kerr, K. AU - Oudkerk, M. AU - Senan, S. AU - Waller, D. AU - Vansteenkiste, J. PY - 2017 DA - 2017// TI - Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up JO - Ann Oncol VL - 28 ID - Postmus2017 ER - TY - JOUR AU - Choi, H. S. AU - Jeong, B. K. AU - Jeong, H. AU - Lee, Y. H. AU - Ha, I. B. AU - Song, J. H. PY - 2017 DA - 2017// TI - Application of the new 8th TNM staging system for non-small cell lung cancer: treated with curative concurrent chemoradiotherapy JO - Radiat Oncol VL - 12 ID - Choi2017 ER - TY - JOUR AU - Ettinger, D. S. AU - Aisner, D. L. AU - Wood, D. E. AU - Akerley, W. AU - Bauman, J. AU - Chang, J. Y. PY - 2018 DA - 2018// TI - NCCN guidelines insights: non–small cell lung cancer, version 5.2018 JO - J Natl Compr Cancer Netw VL - 16 ID - Ettinger2018 ER - TY - JOUR AU - Käsmann, L. AU - Niyazi, M. AU - Blanck, O. AU - Baues, C. AU - Baumann, R. AU - Dobiasch, S. PY - 2018 DA - 2018// TI - Predictive and prognostic value of tumor volume and its changes during radical radiotherapy of stage III non-small cell lung cancer JO - Strahlenther Onkol VL - 194 ID - Käsmann2018 ER - TY - JOUR AU - Taugner, J. AU - Käsmann, L. AU - Eze, C. AU - Dantes, M. AU - Roengvoraphoj, O. AU - Gennen, K. PY - 2019 DA - 2019// TI - Survival score to characterize prognosis in inoperable stage III NSCLC after chemoradiotherapy JO - Transl Lung Cancer Res VL - 8 ID - Taugner2019 ER - TY - JOUR AU - Abdel-Rahman, O. PY - 2018 DA - 2018// TI - Outcomes of surgery as part of the Management of Metastatic non–small-cell lung cancer: a surveillance, epidemiology and end results database analysis JO - Cancer Investig VL - 36 ID - Abdel-Rahman2018 ER - TY - JOUR AU - Walraven, I. AU - Damhuis, R. AU - Berge, M. AU - Rosskamp, M. AU - Eycken, L. AU - Ruysscher, D. PY - 2017 DA - 2017// TI - Treatment variation of sequential versus concurrent Chemoradiotherapy in stage III non-small cell lung cancer patients in the Netherlands and Belgium JO - Clin Oncol VL - 29 ID - Walraven2017 ER - TY - JOUR AU - Antonia, S. J. AU - Villegas, A. AU - Daniel, D. AU - Vicente, D. AU - Murakami, S. AU - Hui, R. PY - 2018 DA - 2018// TI - Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC JO - N Engl J Med VL - 379 ID - Antonia2018 ER - TY - JOUR AU - Käsmann, L. AU - Eze, C. AU - Dantes, M. AU - Roengvoraphoj, O. AU - Niyazi, M. AU - Belka, C. PY - 2019 DA - 2019// TI - State of clinical research of radiotherapy/chemoradiotherapy and immune checkpoint inhibitor therapy combinations in solid tumours—a German radiation oncology survey JO - Eur J Cancer VL - 108 ID - Käsmann2019 ER - TY - JOUR AU - Käsmann, L. AU - Taugner, J. AU - Manapov, F. PY - 2019 DA - 2019// TI - Chemo−/immuno−/radiotherapy combination in treatment of solid cancer JO - Oncotarget VL - 10 ID - Käsmann2019 ER - TY - STD TI - O’Rourke N, iFiguls MR, Bernadó NF, Macbeth F. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev. 2010;6:1465–858. ID - ref11 ER - TY - JOUR AU - Borghaei, H. AU - Paz-Ares, L. AU - Horn, L. AU - Spigel, D. R. AU - Steins, M. AU - Ready, N. E. PY - 2015 DA - 2015// TI - Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer JO - N Engl J Med VL - 373 ID - Borghaei2015 ER - TY - JOUR AU - Brahmer, J. AU - Reckamp, K. L. AU - Baas, P. AU - Crinò, L. AU - Eberhardt, W. E. AU - Poddubskaya, E. PY - 2015 DA - 2015// TI - Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer JO - N Engl J Med VL - 373 ID - Brahmer2015 ER - TY - JOUR AU - Gandhi, L. AU - Rodríguez-Abreu, D. AU - Gadgeel, S. AU - Esteban, E. AU - Felip, E. AU - Angelis, F. PY - 2018 DA - 2018// TI - Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer JO - N Engl J Med VL - 378 ID - Gandhi2018 ER - TY - JOUR AU - Paz-Ares, L. AU - Luft, A. AU - Vicente, D. AU - Tafreshi, A. AU - Gümüş, M. AU - Mazières, J. PY - 2018 DA - 2018// TI - Pembrolizumab plus chemotherapy for squamous non–small-cell lung cancer JO - N Engl J Med VL - 379 ID - Paz-Ares2018 ER - TY - JOUR AU - Foster, C. C. AU - Sher, D. J. AU - Rusthoven, C. G. AU - Verma, V. AU - Spiotto, M. T. AU - Weichselbaum, R. R. PY - 2019 DA - 2019// TI - Overall survival according to immunotherapy and radiation treatment for metastatic non-small-cell lung cancer: a National Cancer Database analysis JO - Radiat Oncol VL - 14 UR - https://doi.org/10.1186/s13014-019-1222-3 DO - 10.1186/s13014-019-1222-3 ID - Foster2019 ER - TY - JOUR AU - Lauber, K. AU - Ernst, A. AU - Orth, M. AU - Herrmann, M. AU - Belka, C. PY - 2012 DA - 2012// TI - Dying cell clearance and its impact on the outcome of tumor radiotherapy JO - Front Oncol VL - 2 ID - Lauber2012 ER - TY - JOUR AU - Olive, P. L. PY - 1998 DA - 1998// TI - The role of DNA single-and double-strand breaks in cell killing by ionizing radiation JO - Radiat Res VL - 150 ID - Olive1998 ER - TY - JOUR AU - Frey, B. AU - Rückert, M. AU - Deloch, L. AU - Rühle, P. F. AU - Derer, A. AU - Fietkau, R. PY - 2017 DA - 2017// TI - Immunomodulation by ionizing radiation—impact for design of radio-immunotherapies and for treatment of inflammatory diseases JO - Immunol Rev VL - 280 ID - Frey2017 ER - TY - JOUR AU - Abuodeh, Y. AU - Venkat, P. AU - Kim, S. PY - 2016 DA - 2016// TI - Systematic review of case reports on the abscopal effect JO - Curr Probl Cancer VL - 40 ID - Abuodeh2016 ER - TY - JOUR AU - Ng, J. AU - Dai, T. PY - 2016 DA - 2016// TI - Radiation therapy and the abscopal effect: a concept comes of age JO - Ann Transl Med VL - 4 ID - Ng2016 ER - TY - JOUR AU - Grass, G. D. AU - Krishna, N. AU - Kim, S. PY - 2016 DA - 2016// TI - The immune mechanisms of abscopal effect in radiation therapy JO - Curr Probl Cancer VL - 40 ID - Grass2016 ER - TY - JOUR AU - Demaria, S. AU - Ng, B. AU - Devitt, M. L. AU - Babb, J. S. AU - Kawashima, N. AU - Liebes, L. PY - 2004 DA - 2004// TI - Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated JO - Int J Radiat Oncol Biol Phys VL - 58 ID - Demaria2004 ER - TY - JOUR AU - Ko, E. C. AU - Raben, D. AU - Formenti, S. C. PY - 2018 DA - 2018// TI - The integration of radiotherapy with immunotherapy for the treatment of non–small cell lung cancer JO - Clin Cancer Res VL - 24 ID - Ko2018 ER - TY - JOUR AU - Chang, M. -. C. AU - Chen, Y. -. L. AU - Lin, H. -. W. AU - Chiang, Y. -. C. AU - Chang, C. -. F. AU - Hsieh, S. -. F. PY - 2018 DA - 2018// TI - Irradiation enhances abscopal anti-tumor effects of antigen-specific immunotherapy through regulating tumor microenvironment JO - Mol Ther VL - 26 ID - Chang2018 ER - TY - JOUR AU - Gupta, A. AU - Probst, H. C. AU - Vuong, V. AU - Landshammer, A. AU - Muth, S. AU - Yagita, H. PY - 2012 DA - 2012// TI - Radiotherapy promotes tumor-specific effector CD8+ T cells via dendritic cell activation JO - J Immunol VL - 189 ID - Gupta2012 ER - TY - JOUR AU - Qinfeng, S. AU - Depu, W. AU - Xiaofeng, Y. AU - Shah, W. AU - Hongwei, C. AU - Yili, W. PY - 2013 DA - 2013// TI - In situ observation of the effects of local irradiation on cytotoxic and regulatory T lymphocytes in cervical cancer tissue JO - Radiat Res VL - 179 ID - Qinfeng2013 ER - TY - JOUR AU - Son, C. -. H. AU - Bae, J. -. H. AU - Shin, D. -. Y. AU - Lee, H. -. R. AU - Jo, W. -. S. AU - Yang, K. PY - 2015 DA - 2015// TI - Combination effect of regulatory T-cell depletion and ionizing radiation in mouse models of lung and colon cancer JO - Int J Radiat Oncol Biol Phys VL - 92 ID - Son2015 ER - TY - JOUR AU - Reits, E. A. AU - Hodge, J. W. AU - Herberts, C. A. AU - Groothuis, T. A. AU - Chakraborty, M. AU - Wansley, E. K. PY - 2006 DA - 2006// TI - Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy JO - J Exp Med VL - 203 ID - Reits2006 ER - TY - JOUR AU - Sridharan, V. AU - Schoenfeld, J. D. PY - 2015 DA - 2015// TI - Immune effects of targeted radiation therapy for cancer JO - Discov Med VL - 19 ID - Sridharan2015 ER - TY - JOUR AU - Zeng, H. AU - Zhang, W. AU - Gong, Y. AU - Xie, C. PY - 2019 DA - 2019// TI - Radiotherapy activates autophagy to increase CD8+ T cell infiltration by modulating major histocompatibility complex class-I expression in non-small cell lung cancer JO - J Int Med Res VL - 47 ID - Zeng2019 ER - TY - JOUR AU - Dovedi, S. J. AU - Cheadle, E. J. AU - Popple, A. L. AU - Poon, E. AU - Morrow, M. AU - Stewart, R. PY - 2017 DA - 2017// TI - Fractionated radiation therapy stimulates antitumor immunity mediated by both resident and infiltrating polyclonal T-cell populations when combined with PD-1 blockade JO - Clin Cancer Res VL - 23 ID - Dovedi2017 ER - TY - JOUR AU - Choe, E. -. A. AU - Cha, Y. J. AU - Kim, J. -. H. AU - Pyo, K. H. AU - Hong, M. H. AU - Park, S. Y. PY - 2019 DA - 2019// TI - Dynamic changes in PD-L1 expression and CD8+ T cell infiltration in non-small cell lung cancer following chemoradiation therapy JO - Lung Cancer VL - 136 ID - Choe2019 ER - TY - JOUR AU - Fujimoto, D. AU - Uehara, K. AU - Sato, Y. AU - Sakanoue, I. AU - Ito, M. AU - Teraoka, S. PY - 2017 DA - 2017// TI - Alteration of PD-L1 expression and its prognostic impact after concurrent chemoradiation therapy in non-small cell lung cancer patients JO - Sci Rep VL - 7 ID - Fujimoto2017 ER - TY - JOUR AU - Kim, J. -. Y. AU - Son, Y. -. O. AU - Park, S. -. W. AU - Bae, J. -. H. AU - Chung, J. S. AU - Kim, H. H. PY - 2006 DA - 2006// TI - Increase of NKG2D ligands and sensitivity to NK cell-mediated cytotoxicity of tumor cells by heat shock and ionizing radiation JO - Exp Mol Med VL - 38 ID - Kim2006 ER - TY - JOUR AU - Gasser, S. AU - Orsulic, S. AU - Brown, E. J. AU - Raulet, D. H. PY - 2005 DA - 2005// TI - The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor JO - Nature VL - 436 ID - Gasser2005 ER - TY - JOUR AU - Burnette, B. C. AU - Liang, H. AU - Lee, Y. AU - Chlewicki, L. AU - Khodarev, N. N. AU - Weichselbaum, R. R. PY - 2011 DA - 2011// TI - The efficacy of radiotherapy relies upon induction of type I interferon–dependent innate and adaptive immunity JO - Cancer Res VL - 71 ID - Burnette2011 ER - TY - JOUR AU - Zhang, J. AU - Nakatsugawa, S. AU - Niwa, O. AU - Ju, G. AU - Liu, S. PY - 1994 DA - 1994// TI - Ionizing radiation-induced IL-1 alpha, IL-6 and GM-CSF production by human lung cancer cells JO - Chin Med J VL - 107 ID - Zhang1994 ER - TY - JOUR AU - Dong, X. -. R. AU - Wang, J. -. N. AU - Liu, L. AU - Chen, X. AU - Chen, M. -. S. AU - Chen, J. PY - 2010 DA - 2010// TI - Modulation of radiation-induced tumour necrosis factor-α and transforming growth factor β1 expression in the lung tissue by Shengqi Fuzheng injection JO - Mol Med Rep VL - 3 ID - Dong2010 ER - TY - JOUR AU - Golden, E. B. AU - Frances, D. AU - Pellicciotta, I. AU - Demaria, S. AU - Helen Barcellos-Hoff, M. AU - Formenti, S. C. PY - 2014 DA - 2014// TI - Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death JO - Oncoimmunology VL - 3 ID - Golden2014 ER - TY - JOUR AU - Käsmann, L. AU - Eze, C. AU - Manapov, F. PY - 2020 DA - 2020// TI - Stereotactic body radiation therapy (SBRT) combined with immune check-point inhibition (ICI) in advanced lung cancer: which metastatic site should be irradiated to induce immunogenic cell death? JO - Int J Radiat Oncol Biol Phys VL - S0360-3016 ID - Käsmann2020 ER - TY - JOUR AU - Mondini, M. AU - Nizard, M. AU - Tran, T. AU - Mauge, L. AU - Loi, M. AU - Clémenson, C. PY - 2015 DA - 2015// TI - Synergy of radiotherapy and a cancer vaccine for the treatment of HPV-associated head and neck cancer JO - Mol Cancer Ther VL - 14 ID - Mondini2015 ER - TY - JOUR AU - Matsumura, S. AU - Wang, B. AU - Kawashima, N. AU - Braunstein, S. AU - Badura, M. PY - 2008 DA - 2008// TI - Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells JO - J Immunol VL - 181 ID - Matsumura2008 ER - TY - JOUR AU - Chakravarty, P. K. AU - Alfieri, A. AU - Thomas, E. K. AU - Beri, V. AU - Tanaka, K. E. AU - Vikram, B. PY - 1999 DA - 1999// TI - Flt3-ligand administration after radiation therapy prolongs survival in a murine model of metastatic lung cancer JO - Cancer Res VL - 59 ID - Chakravarty1999 ER - TY - JOUR AU - Lee, Y. AU - Auh, S. L. AU - Wang, Y. AU - Burnette, B. AU - Wang, Y. AU - Meng, Y. PY - 2009 DA - 2009// TI - Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment JO - Blood VL - 114 ID - Lee2009 ER - TY - JOUR AU - Zheng, H. AU - Zeltsman, M. AU - Zauderer, M. G. AU - Eguchi, T. AU - Vaghjiani, R. G. AU - Adusumilli, P. S. PY - 2017 DA - 2017// TI - Chemotherapy-induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy JO - Immunotherapy VL - 9 ID - Zheng2017 ER - TY - JOUR AU - Gameiro, S. R. AU - Caballero, J. A. AU - Hodge, J. W. PY - 2012 DA - 2012// TI - Defining the molecular signature of chemotherapy-mediated lung tumor phenotype modulation and increased susceptibility to T-cell killing JO - Cancer Biother Radiopharm VL - 27 ID - Gameiro2012 ER - TY - JOUR AU - Okita, R. AU - Yukawa, T. AU - Nojima, Y. AU - Maeda, A. AU - Saisho, S. AU - Shimizu, K. PY - 2016 DA - 2016// TI - MHC class I chain-related molecule a and B expression is upregulated by cisplatin and associated with good prognosis in patients with non-small cell lung cancer JO - Cancer Immunol Immunother VL - 65 ID - Okita2016 ER - TY - JOUR AU - Boeckman, H. J. AU - Trego, K. S. AU - Turchi, J. J. PY - 2005 DA - 2005// TI - Cisplatin sensitizes cancer cells to ionizing radiation via inhibition of nonhomologous end joining JO - Mol Cancer Res VL - 3 ID - Boeckman2005 ER - TY - JOUR AU - Liu, M. AU - Ma, S. AU - Liu, M. AU - Hou, Y. AU - Liang, B. AU - Su, X. PY - 2014 DA - 2014// TI - Synergistic killing of lung cancer cells by cisplatin and radiation via autophagy and apoptosis JO - Oncol Lett VL - 7 ID - Liu2014 ER - TY - STD TI - Davou GI, Chuwang NJ, Essien UC, Choji TPP, Echeonwu BC, Lugos MD. Cytotoxicity analysis of etoposide and cisplatin on cell lines from human lung cancer and normal human lung. Int Res J Med Med Sci. 2019;7(2):40–7. ID - ref51 ER - TY - JOUR AU - Johnson, T. S. AU - Terrell, C. E. AU - Millen, S. H. AU - Katz, J. D. AU - Hildeman, D. A. AU - Jordan, M. B. PY - 2014 DA - 2014// TI - Etoposide selectively ablates activated T cells to control the immunoregulatory disorder hemophagocytic lymphohistiocytosis JO - J Immunol VL - 192 ID - Johnson2014 ER - TY - JOUR AU - Ferraro, C. AU - Quemeneur, L. AU - Fournel, S. AU - Prigent, A. AU - Revillard, J. AU - Bonnefoy-Berard, N. PY - 2000 DA - 2000// TI - The topoisomerase inhibitors camptothecin and etoposide induce a CD95-independent apoptosis of activated peripheral lymphocytes JO - Cell Death Differ VL - 7 ID - Ferraro2000 ER - TY - JOUR AU - Stahnke, K. AU - Fulda, S. AU - Friesen, C. AU - Strauß, G. AU - Debatin, K. -. M. PY - 2001 DA - 2001// TI - Activation of apoptosis pathways in peripheral blood lymphocytes by in vivo chemotherapy JO - Blood J Am Soc Hematol VL - 98 ID - Stahnke2001 ER - TY - JOUR AU - Schaer, D. A. AU - Geeganage, S. AU - Amaladas, N. AU - Lu, Z. H. AU - Rasmussen, E. R. AU - Sonyi, A. PY - 2019 DA - 2019// TI - The folate pathway inhibitor pemetrexed pleiotropically enhances effects of cancer immunotherapy JO - Clin Cancer Res VL - 25 ID - Schaer2019 ER - TY - JOUR AU - Orth, M. AU - Unger, K. AU - Schoetz, U. AU - Belka, C. AU - Lauber, K. PY - 2018 DA - 2018// TI - Taxane-mediated radiosensitization derives from chromosomal missegregation on tripolar mitotic spindles orchestrated by AURKA and TPX2 JO - Oncogene VL - 37 ID - Orth2018 ER - TY - JOUR AU - Zhu, L. AU - Chen, L. PY - 2019 DA - 2019// TI - Progress in research on paclitaxel and tumor immunotherapy JO - Cell Mol Biol Lett VL - 24 ID - Zhu2019 ER - TY - JOUR AU - Formenti, S. C. AU - Rudqvist, N. -. P. AU - Golden, E. AU - Cooper, B. AU - Wennerberg, E. AU - Lhuillier, C. PY - 2018 DA - 2018// TI - Radiotherapy induces responses of lung cancer to CTLA-4 blockade JO - Nat Med VL - 24 ID - Formenti2018 ER - TY - JOUR AU - Dewan, M. Z. AU - Galloway, A. E. AU - Kawashima, N. AU - Dewyngaert, J. K. AU - Babb, J. S. AU - Formenti, S. C. PY - 2009 DA - 2009// TI - Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti–CTLA-4 antibody JO - Clin Cancer Res VL - 15 ID - Dewan2009 ER - TY - JOUR AU - Reck, M. AU - Rodríguez-Abreu, D. AU - Robinson, A. G. AU - Hui, R. AU - Csőszi, T. AU - Fülöp, A. PY - 2016 DA - 2016// TI - Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer JO - N Engl J Med VL - 375 ID - Reck2016 ER - TY - JOUR AU - Hellmann, M. D. AU - Rizvi, N. A. AU - Goldman, J. W. AU - Gettinger, S. N. AU - Borghaei, H. AU - Brahmer, J. R. PY - 2017 DA - 2017// TI - Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study JO - Lancet Oncol VL - 18 ID - Hellmann2017 ER - TY - JOUR AU - Antonia, S. J. AU - Villegas, A. AU - Daniel, D. AU - Vicente, D. AU - Murakami, S. AU - Hui, R. PY - 2017 DA - 2017// TI - Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer JO - N Engl J Med VL - 377 ID - Antonia2017 ER - TY - JOUR AU - Luo, R. AU - Firat, E. AU - Gaedicke, S. AU - Guffart, E. AU - Watanabe, T. AU - Niedermann, G. PY - 2019 DA - 2019// TI - Cisplatin facilitates radiation-induced abscopal effects in conjunction with PD-1 checkpoint blockade through CXCR3/CXCL10-mediated T cell recruitment JO - Clin Cancer Res VL - 25 ID - Luo2019 ER - TY - JOUR AU - Krummel, M. F. AU - Allison, J. P. PY - 1995 DA - 1995// TI - CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation JO - J Exp Med VL - 182 ID - Krummel1995 ER - TY - JOUR AU - Lee, K. -. M. AU - Chuang, E. AU - Griffin, M. AU - Khattri, R. AU - Hong, D. K. AU - Zhang, W. PY - 1998 DA - 1998// TI - Molecular basis of T cell inactivation by CTLA-4 JO - Science VL - 282 ID - Lee1998 ER - TY - JOUR AU - Golden, E. B. AU - Demaria, S. AU - Schiff, P. B. AU - Chachoua, A. AU - Formenti, S. C. PY - 2013 DA - 2013// TI - An abscopal response to radiation and ipilimumab in a patient with metastatic non–small cell lung cancer JO - Cancer Immunol Res VL - 1 ID - Golden2013 ER - TY - JOUR AU - Rizvi, N. A. AU - Hellmann, M. D. AU - Brahmer, J. R. AU - Juergens, R. A. AU - Borghaei, H. AU - Gettinger, S. PY - 2016 DA - 2016// TI - Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non–small-cell lung cancer JO - J Clin Oncol VL - 34 ID - Rizvi2016 ER - TY - JOUR AU - Alsaab, H. O. AU - Sau, S. AU - Alzhrani, R. AU - Tatiparti, K. AU - Bhise, K. AU - Kashaw, S. K. PY - 2017 DA - 2017// TI - PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome JO - Front Pharmacol VL - 8 ID - Alsaab2017 ER - TY - JOUR AU - Deng, L. AU - Liang, H. AU - Burnette, B. AU - Beckett, M. AU - Darga, T. AU - Weichselbaum, R. R. PY - 2014 DA - 2014// TI - Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice JO - J Clin Invest VL - 124 ID - Deng2014 ER - TY - JOUR AU - Zou, W. AU - Wolchok, J. D. AU - Chen, L. PY - 2016 DA - 2016// TI - PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations JO - Sci Transl Med VL - 8 ID - Zou2016 ER - TY - JOUR AU - Reynders, K. AU - Wauters, E. AU - Moisse, M. AU - Decaluwé, H. AU - Leyn, P. AU - Peeters, S. PY - 2018 DA - 2018// TI - RNA-sequencing in non-small cell lung cancer shows gene downregulation of therapeutic targets in tumor tissue compared to non-malignant lung tissue JO - Radiat Oncol VL - 13 ID - Reynders2018 ER - TY - JOUR AU - Boffa, D. J. AU - Graf, R. P. AU - Salazar, M. C. AU - Hoag, J. AU - Lu, D. AU - Krupa, R. PY - 2017 DA - 2017// TI - Cellular expression of PD-L1 in the peripheral blood of lung cancer patients is associated with worse survival JO - Cancer Epidemiol Prev Biomark VL - 26 ID - Boffa2017 ER - TY - JOUR AU - Arrieta, O. AU - Montes-Servín, E. AU - Hernandez-Martinez, J. -. M. AU - Cardona, A. F. AU - Casas-Ruiz, E. AU - Crispín, J. C. PY - 2017 DA - 2017// TI - Expression of PD-1/PD-L1 and PD-L2 in peripheral T-cells from non-small cell lung cancer patients JO - Oncotarget VL - 8 ID - Arrieta2017 ER - TY - JOUR AU - Daly, M. E. AU - Monjazeb, A. M. AU - Kelly, K. PY - 2015 DA - 2015// TI - Clinical trials integrating immunotherapy and radiation for non–small-cell lung cancer JO - J Thorac Oncol VL - 10 ID - Daly2015 ER - TY - STD TI - Herter-Sprie GS, Koyama S, Korideck H, Hai J, Deng J, Li YY, et al. Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer. JCI Insight. 2016;1(9):e87415. ID - ref75 ER - TY - JOUR AU - Gong, X. AU - Li, X. AU - Jiang, T. AU - Xie, H. AU - Zhu, Z. AU - Zhou, F. PY - 2017 DA - 2017// TI - Combined radiotherapy and anti–PD-L1 antibody synergistically enhances antitumor effect in non–small cell lung cancer JO - J Thorac Oncol VL - 12 ID - Gong2017 ER - TY - JOUR AU - Dovedi, S. AU - Illidge, T. PY - 2015 DA - 2015// TI - The antitumor immune response generated by fractionated radiation therapy may be limited by tumor cell adaptive resistance and can be circumvented by PD-L1 blockade JO - Oncoimmunology VL - 4 ID - Dovedi2015 ER - TY - JOUR AU - Chen, G. AU - Huang, A. C. AU - Zhang, W. AU - Zhang, G. AU - Wu, M. AU - Xu, W. PY - 2018 DA - 2018// TI - Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response JO - Nature VL - 560 ID - Chen2018 ER - TY - JOUR AU - Wang, A. AU - Wang, H. AU - Liu, Y. AU - Zhao, M. AU - Zhang, H. AU - Lu, Z. PY - 2015 DA - 2015// TI - The prognostic value of PD-L1 expression for non-small cell lung cancer patients: a meta-analysis JO - Eur J Surg Oncol EJSO VL - 41 ID - Wang2015 ER - TY - JOUR AU - Gennen, K. AU - Käsmann, L. AU - Taugner, J. AU - Eze, C. AU - Karin, M. AU - Roengvoraphoj, O. PY - 2020 DA - 2020// TI - Prognostic value of PD-L1 expression on tumor cells combined with CD8+ TIL density in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy JO - Radiat Oncol VL - 15 ID - Gennen2020 ER - TY - JOUR AU - Liu, Y. AU - Dong, Y. AU - Kong, L. AU - Shi, F. AU - Zhu, H. AU - Yu, J. PY - 2018 DA - 2018// TI - Abscopal effect of radiotherapy combined with immune checkpoint inhibitors JO - J Hematol OncolJ Hematol Oncol VL - 11 UR - https://doi.org/10.1186/s13045-018-0647-8 DO - 10.1186/s13045-018-0647-8 ID - Liu2018 ER - TY - JOUR AU - Dovedi, S. J. AU - Adlard, A. L. AU - Lipowska-Bhalla, G. AU - McKenna, C. AU - Jones, S. AU - Cheadle, E. J. PY - 2014 DA - 2014// TI - Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade JO - Cancer Res VL - 74 ID - Dovedi2014 ER - TY - STD TI - Wang W, Green M, Liu JR, Lawrence TS, Zou W. CD8+ T cells in immunotherapy, radiotherapy, and chemotherapy. In: Oncoimmunology. Cham: Springer; 2018. p. 23–39. ID - ref83 ER - TY - JOUR AU - Vanpouille-Box, C. AU - Alard, A. AU - Aryankalayil, M. J. AU - Sarfraz, Y. AU - Diamond, J. M. AU - Schneider, R. J. PY - 2017 DA - 2017// TI - DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity JO - Nat Commun VL - 8 ID - Vanpouille-Box2017 ER - TY - JOUR AU - Antonia, S. J. AU - Villegas, A. AU - Daniel, D. AU - Vicente, D. AU - Murakami, S. AU - Hui, R. PY - 2018 DA - 2018// TI - Overall survival with Durvalumab after Chemoradiotherapy in stage III NSCLC JO - N Engl J Med VL - 379 UR - https://doi.org/10.1056/NEJMoa1809697 DO - 10.1056/NEJMoa1809697 ID - Antonia2018 ER - TY - STD TI - Bradley JD, Nishio M, Okamoto I, Newton MD, Trani L, Shire NJ, et al. PACIFIC-2: phase 3 study of concurrent durvalumab and platinum-based chemoradiotherapy in patients with unresectable, stage III NSCLC. J Clin Oncol. 2019;37:–TPS8573. https://doi.org/10.1200/JCO.2019.37.15_suppl.TPS8573. ID - ref86 ER - TY - JOUR AU - Wu, Y. AU - Wang, L. AU - Sendur, M. AU - Kim, Y. AU - Zhu, Z. AU - Cheng, Y. PY - 2019 DA - 2019// TI - 339TiP PACIFIC-5: phase III study of durvalumab after either concurrent or sequential chemoradiotherapy (CRT) in patients with stage III NSCLC JO - Ann Oncol VL - 30 ID - Wu2019 ER - TY - JOUR AU - Herbst, R. AU - Barlesi, F. AU - Paz-Ares, L. AU - Raben, D. AU - Aggarwal, C. AU - Bothos, J. PY - 2019 DA - 2019// TI - P1. 04-28 COAST: Durvalumab alone or with novel agents for locally advanced, Unresectable, stage III non-small cell lung cancer JO - J Thorac Oncol VL - 14 ID - Herbst2019 ER - TY - JOUR AU - Lin, S. H. AU - Lin, Y. AU - Price, J. AU - Parker, M. AU - Gomez, D. R. AU - Welsh, J. W. PY - 2017 DA - 2017// TI - DETERRED: PD-L1 blockade to evaluate the safety of lung cancer therapy using carboplatin, paclitaxel, and radiation combined with MPDL3280A (atezolizumab) JO - J Clin Oncol VL - 35 UR - https://doi.org/10.1200/JCO.2017.35.15_suppl.3064 DO - 10.1200/JCO.2017.35.15_suppl.3064 ID - Lin2017 ER - TY - JOUR AU - Lin, S. AU - Lin, X. AU - Clay, D. AU - Yao, L. AU - Mok, I. AU - Gomez, D. PY - 2018 DA - 2018// TI - OA01.06 DETERRED: phase II trial combining Atezolizumab concurrently with Chemoradiation therapy in locally advanced non-small cell lung cancer JO - J Thorac Oncol VL - 13 UR - https://doi.org/10.1016/j.jtho.2018.08.237 DO - 10.1016/j.jtho.2018.08.237 ID - Lin2018 ER - TY - JOUR AU - Peters, S. AU - Felip, E. AU - Dafni, U. AU - Belka, C. AU - Guckenberger, M. AU - Irigoyen, A. PY - 2019 DA - 2019// TI - Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-the ETOP NICOLAS trial JO - Lung Cancer Amst Neth VL - 133 UR - https://doi.org/10.1016/j.lungcan.2019.05.001 DO - 10.1016/j.lungcan.2019.05.001 ID - Peters2019 ER - TY - JOUR AU - Durm, G. A. AU - Althouse, S. K. AU - Sadiq, A. A. AU - Jalal, S. I. AU - Jabbour, S. AU - Zon, R. PY - 2018 DA - 2018// TI - Phase II trial of concurrent chemoradiation with consolidation pembrolizumab in patients with unresectable stage III non-small cell lung cancer: Hoosier cancer research network LUN 14-179 JO - J Clin Oncol VL - 36 UR - https://doi.org/10.1200/JCO.2018.36.15_suppl.8500 DO - 10.1200/JCO.2018.36.15_suppl.8500 ID - Durm2018 ER - TY - STD TI - Anouti B, Althouse S, Durm G, Hanna N. Prognostic variables associated with improved outcomes in patients with stage III NSCLC treated with chemoradiation followed by consolidation Pembrolizumab: a subset analysis of a phase II study from the Hoosier cancer research network LUN 14-179. Clin Lung Cancer. 2020;21(3):288–93. https://doi.org/10.1016/j.cllc.2019.06.009. ID - ref93 ER - TY - STD TI - Jabbour SK, Berman AT, Decker RH, et al. Phase 1 trial of Pembrolizumab administered concurrently with Chemoradiotherapy for locally advanced non–small cell lung cancer: a nonrandomized controlled trial. JAMA Oncol. 2020;6(6):848–55. https://doi.org/10.1001/jamaoncol.2019.6731. ID - ref94 ER - TY - STD TI - Peters S, Dafni U, Boyer M, et al. Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for human use (CHMP). Ann Oncol. 2019;30(2):161–5. https://doi.org/10.1093/annonc/mdy553. ID - ref95 ER -